STOCK TITAN
  1. Home
  2. News
  3. DCTH

Delcath Systems Inc - DCTH STOCK NEWS

Welcome to our dedicated news page for Delcath Systems (Ticker: DCTH), a resource for investors and traders seeking the latest updates and insights on Delcath Systems.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Delcath Systems's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Delcath Systems's position in the market.

News
Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024
Rhea-AI Summary
Delcath Systems, Inc. (Nasdaq: DCTH) announced that the Centers for Medicare & Medicaid Services has established a permanent and product-specific J-code (J9248) for HEPZATO, effective on April 1, 2024. The J-code streamlines the billing of Medicare Part B drugs, specifically for the liver-directed treatment of adult patients with metastatic uveal melanoma. This development is expected to facilitate patient access to the treatment, ensuring accurate and efficient reimbursement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.88%
Tags
none
-
News
Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
Rhea-AI Summary
Delcath Systems, Inc. (Nasdaq: DCTH) announced CEO Gerard Michel's participation in a fireside chat at the Lytham Partners 2024 Investor Select Conference, along with virtual one-on-one meetings with investors. The webcasted fireside chat will take place on February 1, 2024, and the webcast will be available for replay. Management will also be participating in virtual one-on-one meetings throughout the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
conferences
-
News
Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT™
Rhea-AI Summary
Delcath Systems, Inc. (Nasdaq: DCTH) announced the first commercial use of HEPZATO KIT for the treatment of metastatic uveal melanoma at Moffitt Cancer Center. Dr. Jonathan S. Zager, the global Lead Investigator for the FOCUS Phase 3 trial, performed the procedure. The company is working with other leading cancer centers to ensure nationwide access to the treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
none
News
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Delcath Systems, Inc. (DCTH) has granted equity awards to two individuals as a material inducement to their employment, totaling the right to purchase an aggregate of 27,000 shares of the company's common stock. The options were granted on December 29, 2023, with an exercise price equal to $4.16. One-third of the options will vest on the first anniversary of the grant date, with the remaining two-thirds vesting in equal monthly installments over the following twenty-four months. The awards were granted in accordance with NASDAQ Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma Research
Rhea-AI Summary
Delcath Systems, an interventional oncology company (Nasdaq: DCTH), published a clinical study in Melanoma Research. The study focused on the impact of melphalan percutaneous hepatic perfusion treatment on the quality of life of patients with metastatic uveal melanoma. The study showed that utilizing Delcath's HDS to administer high-dose melphalan to the liver is well tolerated by patients and does not negatively affect their quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
News
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Delcath Systems, Inc. (Nasdaq: DCTH) announces the granting of equity awards to five individuals as a material inducement to employment. The grant includes the right to purchase 69,000 shares of the Company's common stock with specific vesting terms. The awards were granted in accordance with NASDAQ Listing Rule 5635(c)(4) and the terms of the Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
none
News
Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update
Rhea-AI Summary
Delcath Systems, Inc. (Nasdaq: DCTH) reported business highlights and financial results for Q3 2023, including FDA approval for HEPZATO KIT™, raising $35 million, and partnership with clinical treatment sites. Revenue for the quarter was approximately $0.4 million, with increased R&D and selling, general, and administrative expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.5%
Tags
earnings
-
News
Delcath Systems to Host Third Quarter 2023 Results Call
Rhea-AI Summary
Delcath Systems, Inc. (Nasdaq: DCTH) will host a conference call on November 13, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023. Participants can dial in or access the webcast to join the call. Replay of the conference will be available until November 20, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
conferences earnings
-
News
Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal Cancers
Rhea-AI Summary
Delcath Systems, Inc. announces longer overall survival for patients treated with Chemosat compared to SIRT in a retrospective study on liver-directed therapies for metastatic uveal melanoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.07%
Tags
none
News
Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference
Rhea-AI Summary
Delcath Systems, Inc. to participate in Lytham Partners Fall 2023 Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
conferences
Stock DCTH logo
Delcath Systems Inc

Nasdaq:DCTH

DCTH Rankings

#4088 Ranked by Market Cap
#1117 Ranked by Stock Gains
N/A Ranked by Dividends

DCTH Stock Data

125.92M
21.10M
3.21%
27.87%
3.68%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
New York

About DCTH

delcath systems, inc. (nasdaq- dcth) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. our proprietary product---melphalan hydrochloride for injection for use with the delcath hepatic delivery system (melphalan/hds)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. delcath is in late-stage clinical development in the united states with initial commercial activities in europe, where the melphalan/hds is marketed as a ce marked device under the trade name delcath hepatic chemosat® delivery system for melphalan (chemosat). our commercial strategy for chemosat is to steadily grow clinical adoption in major european markets and utilize physician experience to support appeals for reimbursement. since launch over 250 chemosat treatments have been performed at over 20 leading european cancer centers. in 2016, we launched our focus pivotal study in hepatic dominant ocular